Introduction
The sudden appearance of a circulating inhibitor of antihemophilic globulin (Factor VIII) is an uncommon, but well-documented phenomenon (1) . Most inhibitors are found in individuals belonging to one of four clinical groups: 1) patients with classical hemophilia A (2, 3); 2) normal postpartum females, within the first 6 months after delivery (4, 5); 3) individuals suffering from a wide variety of disease states having, or thought to have, an immunologic setting (e.g., rheumatoid arthritis, penicillin reactions) (6) (7) (8) ; and 4) elderly persons, of both sexes, in prior good health (9) (10) (11) . The nature of these inhibitors has not been clearly defined. Kinetic studies have led some investigators to conclude that Factor VIII is destroyed enzymatically (9) , whereas others interpret their results to indicate stoichiometric inactivation (12, 13) . Chemical studies are consistent with the assumption that Factor VIII in-hibitors are antibodies (2, 3, 13) , but, with one exception (14) , direct evidence for their identification as immunoglobulins is lacking.
For the present investigation three cases, representative of the first three clinical categories, were compared. The interaction of Factor VIII with each inhibitor was studied by a general kinetic approach that will be described in detail; physicochemical and immunological properties of each inhibitor were delineated with appropriate techniques. Results demonstrate that all three inhibitors are IgG-immunoglobulins of pure kappa type, which inactivate Factor VIII by a mechanism consistent with one-to-one stoichiometrv.
Methods

Coagulation methods
For the preparation of plasma, blood was collected into plastic bags, with acid-citrate-dextrose solution as anticoagulant.' Occasional blood samples were drawn with silicone-coated equipment2 into T vol of 0.1 M sodium citrate or 0.1 M sodium oxalate. After centrifugation at 40 C, the platelet-poor plasma was removed, quickfrozen in acetone-dry ice, and stored at -200 C in small aliquots in silicone-coated tubes.
Serum was prepared from blood collected into uncoated glassware without anticoagulant and incubated at 370 C for 18 hours. The clot was removed by centrifugation and the serum stored frozen. Assays for Factors VIII and IX were performed with the kaolin-activated partial thromboplastin time (15, 16) . Substrate plasma samples were prepared with plastic equipment 1 from individuals deficient in Factor VIII or Factor IX, quick-frozen in acetone-dry ice, and stored in small aliquots in silicone-coated tubes at -20°C. Normal plasma, for use as a daily standard, was collected and stored in a similar fashion. To minimize any inactivation of substrate plasma during performance of the test, contact activation was completed before the addition of inhibitor-containing plasma, in a manner similar to that employed by Breckenridge and Ratnoff (9): 0.1-ml aliquots of substrate plasma, 15 mg per ml kaolin suspension, and crude brain cephalin (17) were incubated in glass tubes at 370 C for 8 minutes; at the end of this time 0.1 ml of test sample was added, incubation was allowed to proceed another 30 seconds, and finally 0.1 ml of M/30 CaCl2 was added and the time for clot formation measured. In this system 8 minutes' incubation was found sufficient for maximal activation of the contact system. Standard normal plasma dilution curves were run with every set of experiments. Normal and deficient plasma samples., tested daily in this manner, showed excellent stability over periods of at least 2 to 3 months. Forty standard curves for Factor VIII assays, performed over this period of time, demonstrated the error of the assay to be ± 15%, that is, at all plasma dilutions tested (2% to 50%) the coefficient of variance was less than 7.5%. Twenty normal donors were assayed for Factors VIII and IX, and the mean values of these determinations were used to define 100%, or 100 U per ml. This "unit" has been utilized primarily to avoid ambiguity in the presentation of kinetic data.
Factor XI was measured with artificially depleted substrate plasma, essentially as described by Horowitz, Wilcox, and Fujimoto (18) . Other coagulation tests were performed by standard methods (19, 20 2) Postpartum. This 36-year-old white female developed a severe life-threatening hemorrhagic diathesis, secondary to a circulating anti-Factor VIII, 2 months after the normal delivery of her third child. She had never received transfusions, and her previous pregnancies had been normal. Three months after the onset of the disease her inhibitor concentration began to decrease spontaneously; after 6 months no inhibitor was present, and her Factor VIII level had returned to normal. 3 3) Ulcerative colitis. This 25-year-old white male with ulcerative colitis has received corticosteroid therapy since the onset of his disease at age 16. At age 20 he suddenly developed a severe hemorrhagic syndrome, characterized by a circulating inhibitor to Factor VIII.
Since then it has not been possible to produce significant levels of Factor VIII with replacement therapy, although bleeding is usually least when his intestinal disease is well controlled. 3 Some pertinent coagulation tests are summarized in Table I .
Chemical and immunological methods
Sephadex gel filtration was performed according to Flodin (21 (24) and double diffusion in agar (25) .
To determine the immunologic nature of the Factor VIII inhibitors, mixtures of antiserum and inhibitor fractions purified by starch block electrophoresis were incubated for 1 hour at 37°C, then overnight at 40 C. Precipitates were removed by centrifugation, and supernates were assayed for residual anti-Factor VIII activity. Controls of antiserum alone and inhibitor alone were always included, and all experiments were performed at least in duplicate.
Inhibitor measurement
Inactivation of Factor VIII was studied at 370 C by incubating inhibitor-containing materials with standard normal plasma or with more purified Factor VIII preparations (26) in plastic tubes.5 Samples were removed for Factor VIII assay with plastic pipettes 5 every 2 to 3 minutes during the first 15 minutes of incubation, in order to obtain accurate estimates of the initial velocity of the reaction. Sampling was continued at 15-to 30-minute intervals for a further 105 minutes. Controls at 370 C of Factor VIII alone and inhibitors alone showed no loss of Factor VIII activity for 90 minutes, and only a 10% loss at 2 hours. No corrections have been applied to 2-hour values. Inhibitors were stable for the entire period. The relationship of reaction velocity to temperature was studied in the range of 70 to 400 C. At temperatures below 370 C controls showed no measurable loss of Factor VIII in 2 hours; at 400 C some decrease of Factor VIII was measurable by 1 hour, and all results were corrected for these losses. All kinetic experiments were performed at least twice; most were run in triplicate.
Inhibitor concentrations were expressed in units in a manner similar to that of Biggs and Bidwell (12), except that the definition is based more closely on initial velocities: One unit of inhibitor is that amount which will inactivate 30%o of a 50 U per ml solution of Factor VIII in 15 minutes at 370 C. The source of Factor VIII can be standard normal plasma (diluted 1: 2) or a concentrated preparation (26) . The definition assumes similar time curves for the inactivation of Factor VIII by all inhibitors. That exceptions occur can be documented from the literature (14, 27) and from data in this report. It must be emphasized, therefore, that measurements in "units" may not be comparable for different inhibitors, although very useful in the study of any given case.
Kinetic methods
After qualitative data had demonstrated that the interaction between inhibitor and Factor VIII was nonenzymatic (see Results), the exact stoichiometry of the reaction became of interest. Since one of the inhibitors did not obey time-dependent first-order kinetics at any concentration tested (Figure 1 ), a meaningful kinetic analysis required some other approach. For these purposes the method of initial velocities, originally stated by Van't Hoff (28, 29) , was used:
In a reaction of the type under investigation,
Factor VIII + inhibitor -* products, [1] one can usually, though by no means always, write the velocity as [6] where C = proportionality constant, or log [I] = log C + log [plasma %]. [7] Since log C is a constant, the use of serial dilutions of plasma in Equation 5 , instead of molar concentrations of [I] o, will alter the intercept of the line on the log v axis, but not its slope; hence the value of n calculated will be unchanged. A similar argument holds for Initial velocities, expressed as Factor VIII units per milliliter per minute inactivated, were measured graphically from the initial slopes of kinetic runs. Most points earlier than 10 minutes have been omitted from the graphs, however, for the sake of clarity in reproduction.
Temperature dependence of the reaction has been expressed by means of the Arrhenius equation (30), k = Ae-Ea/RTI [8] where k = reaction constant, R = gas constant, A = "frequency factor" (a constant), Ea = activation energy, and T = absolute temperature. Thus log k = logA -(Ea/2.3R) (1/T).
[9]
Substituting Vinltila for k and plotting log vinittia vs.
( All three inhibitors could be completely neutralized by the serial addition to reaction mixtures of sufficient Factor VIII; a representative experiment is illustrated in Figure 5 . Since the inhibitor plasmas were quite potent, this saturation phenomenon was most easily demonstrated by diluting patient plasmas to inhibitor concentrations of 0.5 to 1.0 U per ml. Results were identical when purified inhibitor fractions were tested. Such saturation phenomena could not be demon- mediate (7 S) peak in gel filtration experiments on Sephadex G-200. When whole inhibitor plasma was gel filtered, no free Factor VIII could be detected under any of the three peaks, although it was easily measured under the first peak in runs with normal plasma. Thus there was no evidence that the inhibitor-Factor VIII complex could be easily dissociated.
Starch block electrophoresis' revealed differences in mobility for the three inhibitors ( Figure 6 ), peak activity varying from a /3 position (ulcerative colitis) to a slow y mobility (hemophilia A). Peak positions were very reproducible, although the degree of trailing varied somewhat from run to run.
Direct evidence of the immunoglobulin nature of the inhibitors was sought in neutralization experiments. Peak inhibitor tubes isolated by starch block electrophoresis were allowed to react overnight with specific antisera to human immunoglobulins. Reactions were carried out in the region of relative antibody (antiserum) excess, as previously determined by maximal precipitation. Results are depicted in Table IV . All three inhibitors were completely and specifically neutralized by anti-IgG antiserum, as well as by antikappa antiserum.
Kinetic analysis. Plots were made from the kinetic data in Tables II and III, E. : 5,945 exist, but it is also possible that the apparent resistance of their inhibitors to neutralization is related to the addition of insufficient quantities of Factor VIII. In the present patients very large amounts of Factor VIII could be inactivated by inhibitor plasmas: 5,160, 1,110, and 7,360 U of Factor VIII were required to neutralize 1 ml of plasma from ulcerative colitis, postpartum, and hemophilia A patients, respectively. To study the stoichiometry of Factor VIII inhibition quantitatively, one must limit the kinetic complexities introduced by back reactions and possible intermediary reactions, both of which may become more significant as the over-all reaction progresses. These considerations are especially important in dealing with antigen-antibody reactions, in which both reactants are multivalent, and are presumably operative in the "exceptional" cases of Factor VIII inhibitors that do not follow simple time-dependent kinetics. In such situations the chemical reaction in incubation mixtures actually may be changing with time, and an explicit mathematical expression of the entire time curve may be nearly impossible to obtain. By utilizing initial velocity measurements one may avoid these pitfalls. He is, of course, assuming that little of the initial reactant (with respect to the total present) has disappeared during the very early course of the reaction. The limits of this assumption can be estimated from the kinetics (Figures 3 and 4) . In the present experiments it is possible to conclude that less than 10% of any reactant has disappeared during the time necessary to measure initial reaction velocities. Thus the coefficients m and n in Equation 2 have a probable error of approximately ±-10%. This approach is especially advantageous in that it allows the analysis of reactions in which concentrations of reactants can only be expressed in arbitrary terms such as "per cent plasma" or biological "units."
The results of this kinetic analysis indicate that inactivation of Factor VIII is first order with respect to inhibitor and with respect to Factor VIII. Although it rarely is permissible to deduce a molecular mechanism from reaction kinetics, the simplest mechanistic conclusion consistent with the observed data is that the inactivation of one molecule of Factor VIII requires its combination with one molecule (or one site on a molecule) of inhibitor. No statement can be made concerning the possibility of subsequent steps, such as the combination of the complex with still another molecule of Factor VIII or inhibitor, even though such may occur.
The chemical nature of Factor VIII inhibitors has not been investigated systematically. Inhibitory activity generally has been found in y-globulin-rich fractions isolated by ammonium sulfate precipitation (1, 13), alcohol fractionation (3, 8, 9) , and electrophoresis (1, 13, 31, 32) ; however, one patient has been reported in whom the electrophoretic y-globulin fraction was devoid of activity (10) . A sedimentation constant of 7 S has been estimated by density gradient centrifugation in a single case (13) , and a similar, or smaller, size can be inferred from the report of transplacental transfer of a circulating anticoagulant (33) .
In the present study, in addition to fractionation techniques, specific immune neutralization was employed to identify directly the chemical nature of the inhibitors. Results demonstrate convincingly that these materials are immunoglobulins of the class IgG. The different electrophoretic mobilities of the three inhibitors, reminiscent of similar findings in myeloma, suggested that they might represent relatively homogeneous subfractions of IgG. Light chain typing (34, 35) confirmed this possibility: All three inhibitors appeared to be exclusively of kappa type.
Normal circulating human immunoglobulins are composed of both Type K (kappa) and Type L (lambda) molecules (36) . Investigations of specific blood group agglutinins (37, 38) , antithyroglobulins (37, 39) , and experimentally produced antidextrans (39) have shown them to be mixtures of active antibody of both types. Multiple myeloma and Waldenstrdm's macroglobulinemia, on the other hand, are characterized by the production of monotypic immunoglobulins (40) , but only rarely has antibody activity been associated with these paraproteins (14, 41, 42) . The syndrome of chronic hemolytic anemia due to cold agglutinins (43) is the only condition known in which monotypic antibody is regularly produced. In 59 reported patients the antibody has been found to be an IgM exclusively of Type K (37, 38, 44) . One case has recently been described due to an IgA cold agglutinin; this antibody, too, was of Type K (45) .
The present report may represent the second syndrome due to production of a monotypic antibody, and the first instance involving IgG immunoglobulins. In none of these patients could cold hemagglutinins be demonstrated.
The production of antibodies in at least one of these patients (hemophilia A) probably is in response to immunization, since this patient has received numerous transfusions from a variety of donors since birth. Antibody production in the postpartum female may reasonably be ascribed to immunization during pregnancy. In both instances the implication is clear that genetic polymorphism for Factor VIII may exist. The fact that these antibodies are monotypic may reflect important antigenic characteristics of the Factor VIII molecule. Experiments are in progress in this laboratory designed to detect allelic forms of Factor VIII.
The lack of reports of monotypic Type L antibodies may have biological significance, since it is known that major differences exist between kappa and lambda light chains (46) . However, in analogy with the myelomas, in which Type K paraproteins are twice as frequent as the Type L variety (40) , it is possible that other monotypic antibody syndromes may be discovered due to Type L immunoglobulins.
Temperature dependence of the present inhibitors is similar to that reported by others (9, 12, 13) although even at 7°C the rate of Factor VIII inactivation was appreciable. Leitner and his colleagues (13) remarked on the unusually great effect of temperature on the inhibitor Factor VIII reaction. But, as these authors point out, similar behavior has been observed in other antibodyantigen reactions (47, 48) in which the rate of the reaction was measured by loss of biological activity. Furthermore, some antibody-hapten reactions, although much more rapid, have shown temperature dependence of the same degree (49) , resulting in activation energies of 4.0 to 4.5 kcal per mole. This figure is quite close to the 6 kcal per mole activation energy calculated for the Factor VIII-inhibitor reaction.
